The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Clinical Intervention Awards, 2010Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
The main objective of this study is to evaluate the effect of ADX48621 (dipraglurant) in reducing levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). ADX48621... -
Clinical Intervention Awards, 2010Acupuncture as a Symptoms & Side Effects Treatment for Fatigue in Parkinson's Disease
Objective/Rationale:
Fatigue affects approximately half of all Parkinson’s disease patients and has a major impact on quality of life and disability. Unfortunately, Parkinson’s medications do not... -
Clinical Intervention Awards, 2010Maintenance of Continuous Plasma Levodopa Levels through Continuous Subcutaneous Carbidopa Administration
Objective/Rationale:
In Parkinson’s disease (PD) therapeutics, carbidopa is used together with levodopa to prevent its breakdown. This investigation will determine whether subcutaneous carbidopa... -
Rapid Response Innovation Awards, 2010Biomarkers and Immunotherapy for Parkinson's Disease
Objective/Rationale:
We theorize that the interplay between the immune system and the brain plays a substantive role in the progression of Parkinson’s disease. Moreover, we posit that the immune system... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2010Development and Screening of Contrast Agents for In-vivo Imaging of Parkinson's Disease
Promising Outcomes of Original Grant:
The goals of the original grant were to screen a library of compounds to identify leads for non-invasive imaging of PD pathology. We used cell culture models of... -
Rapid Response Innovation Awards, 2010Mechanism and Modulation of Alpha-Synuclein Expression
Promising Outcomes of Original Grant:
In the initial grant, we tested the hypothesis that GATA-2 is a direct regulator of alpha-synuclein expression in dopaminergic neurons and therefore represents a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.